EmpiraMed Selected For Novel DTx Interventional Clinical Trial

MAYNARD, Mass., Aug. 10, 2021 /PRNewswire/ -- EmpiraMed, Inc., a digital well being know-how chief within the discipline of Digital Medical Research for Actual World Proof, immediately introduced that Happify Well being chosen EmpiraMed to carry out the interventional medical trial for his or her Ensemble investigational prescription digital therapeutic (DTx) for the aim of FDA regulatory approval consideration. The trial has been deployed utilizing the EmpiraMedTM PRO PortalTM Software program Platform and affected person recruitment has commenced.

"EmpiraMed has demonstrated that they're collaborative, agile, and adaptable, which is ideally suited to the dynamic DTx business," in keeping with Acacia Parks, Chief Science Officer of Happify Well being, who added, "EmpiraMed's revolutionary know-how and strategies allowed us to implement a examine design that's novel, clinically rigorous, and affords examine contributors a really compelling consumer expertise."

EmpiraMed was chosen as a result of their digital examine platform has a confirmed excessive affected person engagement observe file. Greg Erman, President & CEO of EmpiraMed stated, "Sufferers and clinicians will see nice synergy between EmpiraMed's exceptional affected person engagement charges for medical analysis and Happify Well being's personal distinctive affected person expertise for the administration of Ensemble."

Ensemble is the primary and solely transdiagnostic prescription DTx for the remedy of sufferers who've Main Depressive Dysfunction (MDD) or Generalized Nervousness Dysfunction (GAD). Sufferers can be taught extra about collaborating on this trial and gaining access to Ensemble by visiting https://getensemble.com/.

About EmpiraMed

EmpiraMed is a digital well being know-how firm that performs post-market, potential, Digital Medical Research to generate Actual World Proof for the Life Science Business.

 » Read more from www.prnewswire.com